0001231919-23-000063.txt : 20230825 0001231919-23-000063.hdr.sgml : 20230825 20230825162935 ACCESSION NUMBER: 0001231919-23-000063 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20230825 DATE AS OF CHANGE: 20230825 EFFECTIVENESS DATE: 20230825 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Taysha Gene Therapies, Inc. CENTRAL INDEX KEY: 0001806310 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 843199512 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-490724 FILM NUMBER: 231208733 BUSINESS ADDRESS: STREET 1: 3000 PEGASUS PARK DRIVE STREET 2: SUITE 1430 CITY: DALLAS STATE: TX ZIP: 75247 BUSINESS PHONE: (214) 612-0000 MAIL ADDRESS: STREET 1: 3000 PEGASUS PARK DRIVE STREET 2: SUITE 1430 CITY: DALLAS STATE: TX ZIP: 75247 D 1 primary_doc.xml X0708 D LIVE 0001806310 Taysha Gene Therapies, Inc. 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX TEXAS 75247 (214) 612-0000 DELAWARE None None Corporation true 2019 Sean P. Nolan c/o Taysha Gene Therapies, Inc. 3000 Pegasus Park Drive, Suite 1430 Dallas TX TEXAS 75247 Executive Officer Director Kamran Alam c/o Taysha Gene Therapies, Inc. 3000 Pegasus Park Drive, Suite 1430 Dallas TX TEXAS 75247 Executive Officer Sukumar Nagendran c/o Taysha Gene Therapies, Inc. 3000 Pegasus Park Drive, Suite 1430 Dallas TX TEXAS 75247 Executive Officer Director Laura Sepp-Lorenzino c/o Taysha Gene Therapies, Inc. 3000 Pegasus Park Drive, Suite 1430 Dallas TX TEXAS 75247 Director Kathleen Reape c/o Taysha Gene Therapies, Inc. 3000 Pegasus Park Drive, Suite 1430 Dallas TX TEXAS 75247 Director Phillip Donenberg c/o Taysha Gene Therapies, Inc. 3000 Pegasus Park Drive, Suite 1430 Dallas TX TEXAS 75247 Director Sean Stalfort c/o Taysha Gene Therapies, Inc. 3000 Pegasus Park Drive, Suite 1430 Dallas TX TEXAS 75247 Director Biotechnology Decline to Disclose 06b false 2023-08-16 false true true false 0 Jefferies LLC 2347 None None 520 Madison Avenue New York NY NEW YORK 10022 CA CALIFORNIA FL FLORIDA IL ILLINOIS MA MASSACHUSETTS NJ NEW JERSEY NY NEW YORK NC NORTH CAROLINA PA PENNSYLVANIA TX TEXAS VA VIRGINIA false 149997018 149952767 44251 The Company sold pre-funded warrants to purchase 44,250,978 shares of common stock. The purchase price was $0.90 minus the $0.001 exercise price per pre-funded warrant. If exercised, the Company will receive $0.001 for each pre-funded warrant. false 42 0 9000000 0 false Taysha Gene Therapies, Inc. /s/ Kamran Alam Kamran Alam Chief Financial Officer 2023-08-25